HK1217960A1 - 用於 移植的接受體框架 - Google Patents

用於 移植的接受體框架

Info

Publication number
HK1217960A1
HK1217960A1 HK16105985.8A HK16105985A HK1217960A1 HK 1217960 A1 HK1217960 A1 HK 1217960A1 HK 16105985 A HK16105985 A HK 16105985A HK 1217960 A1 HK1217960 A1 HK 1217960A1
Authority
HK
Hong Kong
Prior art keywords
cdr
acceptor framework
grafting
cdr grafting
acceptor
Prior art date
Application number
HK16105985.8A
Other languages
English (en)
Inventor
Dominik Escher
Original Assignee
Esbatech - A Novartis Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech - A Novartis Company Llc filed Critical Esbatech - A Novartis Company Llc
Publication of HK1217960A1 publication Critical patent/HK1217960A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16105985.8A 2013-02-15 2016-05-25 用於 移植的接受體框架 HK1217960A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/053039 WO2014124677A1 (en) 2013-02-15 2013-02-15 Acceptor framework for cdr grafting

Publications (1)

Publication Number Publication Date
HK1217960A1 true HK1217960A1 (zh) 2017-01-27

Family

ID=47716049

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105985.8A HK1217960A1 (zh) 2013-02-15 2016-05-25 用於 移植的接受體框架

Country Status (8)

Country Link
EP (1) EP2956478A1 (zh)
JP (1) JP2016506974A (zh)
CN (1) CN104884470A (zh)
AU (1) AU2013378628A1 (zh)
CA (1) CA2894918A1 (zh)
HK (1) HK1217960A1 (zh)
RU (1) RU2015139095A (zh)
WO (1) WO2014124677A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283512A4 (en) * 2015-04-17 2018-10-03 Distributed Bio Inc Method for mass humanization of non-human antibodies
CN108473987B (zh) * 2016-01-08 2024-01-02 马可讯治疗有限公司 具有改变的多样性支架结构域的结合成员

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6905668B1 (en) 1998-09-25 2005-06-14 Tokyo Gas Company Limited Diagnostic agents for pancreatic exocrine function
EP2392596A3 (en) * 1999-12-28 2013-11-27 ESBATech, an Alcon Biomedical Research Unit LLC Intrabodies with defined framework that is stable in a reducing environment and applications thereof
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
WO2003097697A2 (en) * 2002-05-22 2003-11-27 Esbatech Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
EP1651659A4 (en) 2003-08-07 2008-09-17 Epitomics Inc METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
DK2021463T3 (en) * 2006-05-19 2017-01-16 Alder Biopharmaceuticals Inc Culture method to obtain a cloned population of antigen-specific B cells
NZ601583A (en) 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
WO2008144753A2 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
KR101650165B1 (ko) * 2008-06-25 2016-08-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역결합제의 용해도 최적화
WO2009155723A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
AU2009264567B2 (en) * 2008-06-25 2014-06-12 Novartis Ag Humanization of rabbit antibodies using a universal antibody framework
US8399625B1 (en) * 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting

Also Published As

Publication number Publication date
AU2013378628A1 (en) 2015-06-11
JP2016506974A (ja) 2016-03-07
WO2014124677A1 (en) 2014-08-21
RU2015139095A (ru) 2017-03-21
CA2894918A1 (en) 2014-08-21
EP2956478A1 (en) 2015-12-23
CN104884470A (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
HK1217958A1 (zh) 四價雙特異性抗體
IL246002A0 (en) New methods
EP2832053A4 (en) L3 GATEWAY FOR VXLAN
PL3033808T3 (pl) Rama przytrzymująca dla złączy wtykowych
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
GB201413149D0 (en) No details
PL3003376T3 (pl) Terapie kardiomiopatii
GB201410903D0 (en) No details
GB201421649D0 (en) No details
GB201418212D0 (en) No details
GB201306980D0 (en) Methods
GB201418129D0 (en) No details
HK1223111A1 (zh) 方法
GB201421548D0 (en) No details
GB201408089D0 (en) No details
GB201418214D0 (en) No details
GB201416327D0 (en) No details
GB201312444D0 (en) Methods
GB201407200D0 (en) No details
GB201308516D0 (en) Methods
GB201417843D0 (en) No details
HK1217960A1 (zh) 用於 移植的接受體框架
HK1219485A1 (zh) 用於 移植的受體框架
GB201312238D0 (en) Structural Frame
GB201304234D0 (en) Methods